구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BT-007 CD7 CAR-T cells (BT-007 CD7 CAR-T cells) Bioceltech Therapeutics, Ltd.·T Cell Lymphoblastic Lymphoma 1 trials |
|---|---|
Overview Program | BT-007 CD7 CAR-T cells |
Overview Company | Bioceltech Therapeutics, Ltd. |
Overview Modality | CGT |
Overview Target | T Cell Lymphoblastic Lymphoma |
Overview Indication | T Cell Lymphoblastic Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemia.. Chimeric Antigen Receptor (CAR)-T cell therapy holds considerable promise for the treatment of CD7 + T cell malignancies. However, a major challenge limiting clinical development of CD7-targeted CARs has been fratricide, a process of self-cytotoxicity caused by the shared expression of… |
Toxicology CRS | Reported |
Clinical Safety signal | Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemia.. Chimeric Antigen Receptor (CAR)-T cell therapy holds considerable promise for the treatment of CD7 + T cell malignancies. However, a major challenge limiting clinical development of CD7-targeted CARs has been fratricide, a process of self-cytotoxicity caused by the shared expression of… |
Clinical Program phase | PHASE_1 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BT-007 CD7 CAR-T cells (BT-007 CD7 CAR-T cells) Bioceltech Therapeutics, Ltd.·T Cell Lymphoblastic Lymphoma 1 trials |
|---|---|
Overview Program | BT-007 CD7 CAR-T cells |
Overview Company | Bioceltech Therapeutics, Ltd. |
Overview Modality | CGT |
Overview Target | T Cell Lymphoblastic Lymphoma |
Overview Indication | T Cell Lymphoblastic Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemia.. Chimeric Antigen Receptor (CAR)-T cell therapy holds considerable promise for the treatment of CD7 + T cell malignancies. However, a major challenge limiting clinical development of CD7-targeted CARs has been fratricide, a process of self-cytotoxicity caused by the shared expression of… |
Toxicology CRS | Reported |
Clinical Safety signal | Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemia.. Chimeric Antigen Receptor (CAR)-T cell therapy holds considerable promise for the treatment of CD7 + T cell malignancies. However, a major challenge limiting clinical development of CD7-targeted CARs has been fratricide, a process of self-cytotoxicity caused by the shared expression of… |
Clinical Program phase | PHASE_1 |
추천 비교
추천 비교